APA

De Vries L. C. S., Duarte J. M., De Krijger M., Welting O., Van Hamersveld P. H. P., Van Leeuwen-Hilbers F. W. M., Moerland P. D., Jongejan A., D'Haens G. R., De Jonge W. J. & Wildenberg M. E. (20200214). A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. : Inflammatory bowel diseases.

Chicago

De Vries L C S, Duarte J M, De Krijger M, Welting O, Van Hamersveld P H P, Van Leeuwen-Hilbers F W M, Moerland P D, Jongejan A, D'Haens G R, De Jonge W J and Wildenberg M E. 20200214. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. : Inflammatory bowel diseases.

Harvard

De Vries L. C. S., Duarte J. M., De Krijger M., Welting O., Van Hamersveld P. H. P., Van Leeuwen-Hilbers F. W. M., Moerland P. D., Jongejan A., D'Haens G. R., De Jonge W. J. and Wildenberg M. E. (20200214). A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. : Inflammatory bowel diseases.

MLA

De Vries L C S, Duarte J M, De Krijger M, Welting O, Van Hamersveld P H P, Van Leeuwen-Hilbers F W M, Moerland P D, Jongejan A, D'Haens G R, De Jonge W J and Wildenberg M E. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function. : Inflammatory bowel diseases. 20200214.